홈 > 시장보고서 > 의약품

시장보고서

상품코드

1268544

세계의 안구건조증 시장(2023-2032년)

Global Dry Eye Disease Market Forecast 2023-2032

발행일: 2023년 05월 | 리서치사:

Inkwood Research | 페이지 정보: 영문 237 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 안구건조증 시장 규모는 2023년부터 2032년까지의 예측 기간 동안 5.11%의 CAGR을 나타낼 것으로 예상됩니다. 안구건조증에 대한 유망한 제품 출시, 안구건조증에 대한 새로운 진단 기술의 도입, 다양한 연령대의 안구건조증 발생률 증가는 시장 성장을 가속하고 있습니다.

이 보고서는 세계 안구건조증(Dry Eye Disease) 시장을 조사하여 시장 역학, 시장 분석, 경쟁 상황 등의 종합적인 정보를 제공합니다.

시장 규모와 추정
시장 개요
조사 범위
위기 시나리오 분석
주요 시장 조사 결과
- 안질의 주요 원인이 되는 대기오염
- 다수 안구건조증 질환의 원인이 되는 COVID-19
- 안구건조증 질환 발병 리스크가 높은 아시아인
- 안구건조증 증상을 일으키는 과다한 화면 열람 시간

제3장 시장 역학

주요 촉진요인
- 안구건조증 질환의 새로운 진단 기술 서론
- 안구건조증 질환에 대한 유망한 파이프라인 제품 발매
- 다양한 연령층 안구건조증 발생률과 유병률 증가
주요 억제요인
- 부작용 리스크
- 대체 요법
- 고가의 특수 제품과 복잡한 상환 시나리오

제4장 주요 분석

상위 시장 분석
주요 시장 동향
Porter's Five Forces 분석
- 바이어의 힘
- 공급업체의 힘
- 대체품
- 신규 진출기업
- 산업 경쟁
성장 전망 매핑
시장 성숙도 분석
시장 집중 분석
밸류체인 분석
- 연구개발
- 제조
- 유통업체
- 판매 후 모니터링

제5장 시장 : 유형별

시판약
처방약

제6장 시장 : 제품별

항염증약
- CYCLOSPORINE
- CORTICOSTEROID
- 기타 항염증약
인공눈물
누공 플러그
분비 촉진제
기타

제7장 시장 : 유통 채널별

병원 약국
독립계 약국 및 드럭스토어
온라인 약국

제8장 지역 분석

북미
유럽
아시아태평양
세계 기타 지역

제9장 경쟁 구도

주요 전략적 전개
- 합병과 인수
- 제품 발매와 개발
- 파트너십과 계약
- 사업 확대와 매각
기업 개요
- AFT PHARMACEUTICALS
- ALCON
- Allergan PLC(ABBVIE에 의해 인수)
- BAUSCH HEALTH COMPANIES INC
- JOHNSON & JOHNSON
- LUMENIS
- NOVALIQ GMBH
- NOVARTIS AG
- OASIS MEDICAL
- OTSUKA PHARMACEUTICAL CO LTD
- SANTEN PHARMACEUTICAL CO LTD
- SENTISS PHARMA PRIVATE LIMITED
- SUN PHARMACEUTICAL INDUSTRIES LTD
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- VISUFARMA

LSH 23.05.16

KEY FINDINGS

The global dry eye disease market is forecasted to record a CAGR of 5.11% during the projected period of 2023-2032. The market growth is ascribed to factors such as the launch of promising pipeline products for dry eye disease, the introduction of new diagnostic techniques for dry eye disease, and the increasing incidence of dry eye among different age groups.

MARKET INSIGHTS

Dry eye is a chronic syndrome, progressive depending on the severity and cause. It is a condition when a person does not have tears to lubricate their eyes. Tears are a vital part of maintaining good eye health and assist in ensuring good vision. The syndrome is typically witnessed among older people. However, it is also becoming common among people who spend long hours in front of the computer.

The accurate diagnosis of dry eye disease is pivotal. Whether it is a practice focusing on a subspecialty, such as glaucoma and retina, or a primary anterior segment practice, the symptoms and signs of dry eye disease are widespread across modern lifestyles. Technological advancements are being made in the field of ophthalmology. Leading firms operating in the market continually concentrate on developing novel therapeutics and diagnostics, as well. For instance, TearScience, a subsidiary of Johnson & Johnson, introduced the latest diagnostic system for dry eye disease in the market, named LipiView II Ocular Surface Interferometer.

REGIONAL INSIGHTS

The global dry eye disease market growth evaluation entails the assessment of the Asia-Pacific, Europe, North America, and the Rest of World. The Asia-Pacific is set to grow with the highest CAGR over the forecasting years due to the increasing number of ophthalmologists in countries like China, India, and Japan, providing good treatment and diagnostic services for ophthalmic conditions and the growing ophthalmic education.

COMPETITIVE INSIGHTS

Significant competition exists between key market players for the development of a new treatment for dry eye disease. The highly sustainable competitive advantages through innovation are likely to intensify rivalry among firms. Besides, solid strategies are anticipated to raise the competition in the market studied.

Some of the top companies operating in the market are Johnson & Johnson, Allergan PLC (Acquired by Abbvie), Bausch Health Companies Inc, etc.

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
- 2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
- 2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
- 2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
- 2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
- 3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
- 3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
- 3.2.1. RISK OF SIDE EFFECTS
- 3.2.2. SUBSTITUTE THERAPIES
- 3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
- 4.7.1. RESEARCH AND DEVELOPMENT
- 4.7.2. MANUFACTURING
- 4.7.3. DISTRIBUTORS
- 4.7.4. POST-SALES MONITORING

5. MARKET BY TYPE

5.1. OTC
5.2. PRESCRIPTION

6. MARKET BY PRODUCT

6.1. ANTI-INFLAMMATORY DRUGS
- 6.1.1. CYCLOSPORINE
- 6.1.2. CORTICOSTEROID
- 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS

7. MARKET BY DISTRIBUTION CHANNEL

7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES

8. GEOGRAPHICAL ANALYSIS

8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
- 8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
- 8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
- 8.1.6. COUNTRY ANALYSIS
  - 8.1.6.1. UNITED STATES
  - 8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.2. CANADA
  - 8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
- 8.2.1. MARKET SIZE & ESTIMATES
- 8.2.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
- 8.2.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
- 8.2.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 8.2.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
- 8.2.6. COUNTRY ANALYSIS
  - 8.2.6.1. UNITED KINGDOM
  - 8.2.6.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.2. GERMANY
  - 8.2.6.2.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.3. FRANCE
  - 8.2.6.3.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.4. ITALY
  - 8.2.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.5. BELGIUM
  - 8.2.6.5.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.6. SPAIN
  - 8.2.6.6.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.7. POLAND
  - 8.2.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.2.6.8. REST OF EUROPE
  - 8.2.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
- 8.3.1. MARKET SIZE & ESTIMATES
- 8.3.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
- 8.3.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
- 8.3.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 8.3.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
- 8.3.6. COUNTRY ANALYSIS
  - 8.3.6.1. CHINA
  - 8.3.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.2. JAPAN
  - 8.3.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.3. INDIA
  - 8.3.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.4. SOUTH KOREA
  - 8.3.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.5. INDONESIA
  - 8.3.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.6. THAILAND
  - 8.3.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.7. AUSTRALIA & NEW ZEALAND
  - 8.3.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.3.6.8. REST OF ASIA-PACIFIC
  - 8.3.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
- 8.4.1. MARKET SIZE & ESTIMATES
- 8.4.2. REST OF WORLD DRY EYE DISEASE MARKET DRIVERS
- 8.4.3. REST OF WORLD DRY EYE DISEASE MARKET CHALLENGES
- 8.4.4. REST OF WORLD DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 8.4.5. KEY PLAYERS IN REST OF WORLD DRY EYE DISEASE MARKET
- 8.4.6. REGIONAL ANALYSIS
  - 8.4.6.1. LATIN AMERICA
  - 8.4.6.1.1. LATIN AMERICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.4.6.2. MIDDLE EAST AND AFRICA
  - 8.4.6.2.1. MIDDLE EAST AND AFRICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGERS & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
- 9.2.1. AFT PHARMACEUTICALS
- 9.2.2. ALCON
- 9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
- 9.2.4. BAUSCH HEALTH COMPANIES INC
- 9.2.5. JOHNSON & JOHNSON
- 9.2.6. LUMENIS
- 9.2.7. NOVALIQ GMBH
- 9.2.8. NOVARTIS AG
- 9.2.9. OASIS MEDICAL
- 9.2.10. OTSUKA PHARMACEUTICAL CO LTD
- 9.2.11. SANTEN PHARMACEUTICAL CO LTD
- 9.2.12. SENTISS PHARMA PRIVATE LIMITED
- 9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
- 9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
- 9.2.15. VISUFARMA

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.

US $ 2,500

￦ 3,299,000

PDF (Multi User License)

동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

US $ 3,000

￦ 3,958,000

PDF (Enterprisewide License)

동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

US $ 4,500

￦ 5,938,000